Liver transplantation for acute hepatic failure due to chemotherapy-induced HBV reactivation in lymphoma patients

World Journal of Gastroenterology

Volumn 17, Issue 25, 2011, Pages 3069-3072

  Noterdaeme, Timothée ^a   Longrée, Luc ^b   Bataille, Christian ^b   Deroover, Arnaud ^a   Lamproye, Anne ^a   Delwaide, Jean ^a   Beguin, Yves ^a   Honoré, Pierre ^a   Detry, Olivier ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Cancer; Chemotherapy; Contraindication; Hepatitis B virus; Liver failure; Liver transplantation

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; LAMIVUDINE; MYCOPHENOLIC ACID; PREDNISONE; PROCARBAZINE; RITUXIMAB; TACROLIMUS; VINCRISTINE SULFATE;

ACUTE LIVER FAILURE; ADULT; ARTICLE; BLOOD ANALYSIS; CANCER PATIENT; CASE REPORT; EMERGENCY TREATMENT; FEMALE; GRAFT INFECTION; HEMATOLOGIC MALIGNANCY; HEPATITIS B; HEPATITIS B VIRUS; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; LIVER DISEASE; LIVER FAILURE; LIVER TRANSPLANTATION; MALE; POSITRON EMISSION TOMOGRAPHY; SURVIVAL; VIRUS REACTIVATION;

EID: 79960275902     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v17.i25.3069     Document Type: Article

References (20)

1. Yeo W, Chan PK, Zhong S, Ho WM, Steinberg JL, Tam JS, Hui P, Leung NW, Zee B, Johnson PJ. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000; 62: 299-307
2. Kusumoto S, Tanaka Y, Mizokami M, Ueda R. Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma. Int J Hematol 2009; 90: 13-23
3. Ziakas PD, Karsaliakos P, Mylonakis E. Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma: a meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance. Haematologica 2009; 94: 998-1005
4. Detry O, Honoré P, Meurisse M, Jacquet N. Cancer in transplant recipients. Transplant Proc 2000; 32: 127
5. Kim SG, Chun JM, Jin R, Kim JY, Won DI, Hwang YJ. Living donor liver transplantation for acute hepatic failure caused by reactivation of hepatitis B virus infection after chemotherapy for hematologic malignancy: case reports. Transplant Proc 2010; 42: 843-845
6. Benten D, Sterneck M, Panse J, Rogiers X, Lohse AW. Low recurrence of preexisting extrahepatic malignancies after liver transplantation. Liver Transpl 2008; 14: 789-798
7. Saigal S, Norris S, Srinivasan P, Muiesan P, Rela M, Heaton N, O'Grady J. Successful outcome of orthotopic liver transplantation in patients with preexisting malignant states. Liver Transpl 2001; 7: 11-15
8. Stange MA, Tutarel O, Pischke S, Schneider A, Strassburg CP, Becker T, Barg-Hock H, Bastürk M, Wursthorn K, Cornberg M, Ott M, Greten TF, Manns MP, Wedemeyer H. Fulminant hepatic failure due to chemotherapy-induced hepatitis B reactivation: role of rituximab. Z Gastroenterol 2010; 48: 258-263
9. Dillon R, Hirschfield GM, Allison ME, Rege KP. Fatal reactivation of hepatitis B after chemotherapy for lymphoma. BMJ 2008; 337: a423
10. Law JK, Ho JK, Hoskins PJ, Erb SR, Steinbrecher UP, Yoshida EM. Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations. Leuk Lymphoma 2005; 46: 1085-1089
11. Detry O, De Roover A, Coimbra C, Delwaide J, Hans MF, Delbouille MH, Monard J, Joris J, Damas P, Belaïche J, Meurisse M, Honoré P. Cadaveric liver transplantation for non-acetaminophen fulminant hepatic failure: a 20-year experience. World J Gastroenterol 2007; 13: 1427-1430
12. Detry O, De Roover A, Honore P, Meurisse M. Brain edema and intracranial hypertension in fulminant hepatic failure: pathophysiology and management. World J Gastroenterol 2006; 12: 7405-7412
13. Hung CM, Jeng LB, Lee WC, Yu MC, Kuo LM, Chen MF. Fulminant hepatic failure caused by hepatitis B virus activation after chemotherapy for breast cancer treated with liver transplantation: a case report. Transplant Proc 2003; 35: 387-388
14. Josting A, Wolf J, Diehl V. Hodgkin disease: prognostic factors and treatment strategies. Curr Opin Oncol 2000; 12: 403-411
15. Diehl V, Thomas RK, Re D. Part II: Hodgkin's lymphoma-- diagnosis and treatment. Lancet Oncol 2004; 5: 19-26
16. Engert A, Diehl V, Franklin J, Lohri A, Dörken B, Ludwig WD, Koch P, Hänel M, Pfreundschuh M, Wilhelm M, Trümper L, Aulitzky WE, Bentz M, Rummel M, Sezer O, Müller-Hermelink HK, Hasenclever D, Löffler M. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol 2009; 27: 4548-4554
17. Norris S, Crosbie O, McEntee G, Traynor O, Nolan N, Mc-Cann S, Hegarty J. Orthotopic liver transplantation for veno- occlusive disease complicating autologous bone marrow transplantation. Transplantation 1997; 63: 1521-1524
18. Rosen HR, Martin P, Schiller GJ, Territo M, Lewin DN, Shackleton CR, Busuttil RW. Orthotopic liver transplantation for bone-marrow transplant-associated veno-occlusive disease and graft-versus-host disease of the liver. Liver Transpl Surg 1996; 2: 225-232
19. Dowlati A, Honore P, Damas P, Deprez M, Delwaide J, Fillet G, Beguin Y. Hepatic rejection after orthotopic liver transplantation for hepatic veno-occlusive disease or graftversus- host disease following bone marrow transplantation. Transplantation 1995; 60: 106-109
20. Hojo M, Morimoto T, Maluccio M, Asano T, Morimoto K, Lagman M, Shimbo T, Suthanthiran M. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999; 397: 530-534